Biotechnology has the reputation: high-risk, high-reward, science-driven upside. Drug Manufacturers has the reputation too: boring, steady, dividend-paying giants. Both industries sell medicine for a living, and both claim to be the fundamentally stronger side of Healthcare right now. The Health Score data says the reputations are backwards, at least on average, though the best individual biotech name still beats the best pharma name.
This comes down to three checks: the industry-wide average, each side's flagship stock, and who's actually winning with investors right now. Meet the two names carrying that fight.
Both industries get compared across the three angles that decide who's actually stronger: the broad average, the best individual name, and which one is winning right now.
Round 1: Industry average, who's fundamentally stronger across the board
Drug Manufacturers averages a 4.57 Health Score across its full roster of 54 stocks. Biotechnology averages just 3.47 across 92 stocks, despite housing some of the highest individual scores in all of Healthcare.
The gap comes down to population size, not just quality. Biotechnology has nearly double the number of companies, and most of them are small, pre-revenue names still burning cash toward a drug approval that may never come. Drug Manufacturers skews toward larger, already-commercialized companies, so its average reflects a more mature, more profitable group overall.
That's not just a pattern in this one dataset, it's a structural feature of the industry. Industry-wide estimates have long put the number even starker: historically, around 92% of biopharmaceutical companies are unprofitable at any given time, and roughly 90% of clinical-stage programs never reach FDA approval at all. Health Score is picking up exactly that: hundreds of Biotechnology stocks are, by design, bets on a drug that may never make it to market, while Drug Manufacturers is stocked with companies that already cleared that bar years ago.
Round 2: The flagship names, who's actually the strongest individual company
Zoom into each industry's own most-watched name and the story flips. Regeneron (REGN) carries a 9.0 Health Score, among the highest of any stock in either industry. Eli Lilly (LLY), Drug Manufacturers' own flagship, sits at 8.3. That's Biotechnology's best individual name beating Drug Manufacturers' best individual name, even though the broader industry average runs the other way.
Regeneron backs the score up with real numbers: a 29.65% net profit margin, meaning it keeps almost $30 of every $100 in sales as actual profit, and a 4.13 current ratio, meaning it holds more than $4 in cash and short-term assets for every $1 of short-term debt due.
Eli Lilly is even more profitable, a 34.98% net margin and a 77.78% return on equity, meaning shareholders earned back roughly $78 a year for every $100 invested in the company, but it carries far more debt relative to what it earns: a cash-flow-to-debt ratio of just 0.40, meaning its yearly operating cash flow covers only about 40% of its total debt, against Regeneron's 1.84, where operating cash flow alone could cover its entire debt load nearly twice over. That leverage gap is exactly why Eli Lilly's Health Score sits a full point behind Regeneron's despite the stronger margins.
Round 3: Performance Score, who's actually delivering right now
Neither Health Score number settles this on its own, so the decider comes down to something a balance sheet can't show: which company's flagship drug is actually working right now. Eli Lilly's Performance Score sits at 8.4. Regeneron's sits at 3.9, a gap almost as wide as the Health Score gap in Round 1, just running the other way.
The reason traces straight to what each company's biggest drug is doing right now. Eli Lilly's stock is up 400.71% over five years, powered by Zepbound, which holds nearly 70% share of new prescriptions in the branded obesity market, with Mounjaro and Zepbound together making up more than half of Lilly's total revenue. Regeneron's stock is up just 21.10% over five years and down 4.25% over three, because its own biggest growth driver, the eye medicine Eylea, is facing growing biosimilar competition that executives addressed directly at a recent investor conference, even as newer formulations work to defend the franchise.
Final score: Drug Manufacturers 2, Biotechnology 1
Drug Manufacturers takes the overall win because it holds the broader industry average and the round that actually reflects what's happening in the market right now. Biotechnology's one win is real, Regeneron's own fundamentals are genuinely elite, but elite fundamentals sitting inside a stagnant stock don't help a portfolio the way a compounding one does.
So which side should you actually be watching? Drug Manufacturers is the pick if what you want is the industry currently converting fundamentals into actual returns, with Eli Lilly's GLP-1 dominance as the clearest example. Biotechnology is the pick if you're hunting for individual quality over industry-wide averages, since names like Regeneron prove the sector's best balance sheets can rival anything in pharma, they're just diluted by hundreds of smaller, unprofitable names when you zoom out. Neither read is a signal to buy either stock, it's a scorecard built on where each industry stands today, not a guarantee of where either one trades from here.
Numbers on a page are one thing. Watching Eli Lilly's GLP-1 momentum against Regeneron's Eylea pressure play out side by side is another.
